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S_qary Ovariectomy at I month of age promotes development of hepatocellular ad tous nodule in
female C57BL/6 x DS-F, mice treated ntally with 3' methyl4-dimeth (3'-Me-DAB).
plantation of oestradio170 (E2) peuts at I month of age supprese nodule development. Since E2
incases serm levels of prolactin, high sermn kvel of prolactin in mice that have rceived implants of E2
may play a role m the on of tumorignesis. Terefore, to nmvsigate the role of
prolactin in a r tumorienesis, we amin deveopment of adenomatous nodules in female mice
that had ben ted tal with 3'-Me-DAB and had undergone ovarectomy at I month of age, under
various serum levels of prolactin. Treatment of these mice with perphenazine (dopamine antagonist) from 6
months of age or transplantation of pitumtary glands under the renal capsuk at 6 months of age markedly
increased srm levels of prolactin and sigifiantly supp the of denomatous nodules at 12
months of age. Implantation of E2 ellets at 1 month of age in rm levels of prolactin to a greater
extent and further Cased the ncidenceof adnomatous nodules. Treatment of mice that had ived
implants of E2 pelts at I month of age with birmociptme (dopamine agonist) from 6 months of age
decreased serum levels of prolactin, and was cipanie by an increase in the i of nodules. The
present results showed that an increase m serum ieves of prolactin was accompanied by a dcrease in
of lier tumours inducl by 3'-Me-DAB in mice, ve ffect of prolactin on liver
tumorigenesis in mice. Thus, it is possible that the uppressie ffect of oestrogen on liver tumorigenesis in
mice is mediated, at kast in part, by prolactin-
Ke7wore prolactin; 3'-methyl-4dimethylaminoazobenze; oestrogm
Adminitaton of carcinogens to prepubertal mice induces
de'velopment of hepatocellular tumours. Male mice are more
susceptible than females (Klein and Weisburger, 1966;
Vesselinovitch and Mihailovich, 1967; Vesselinovitch, 1969;
Roe et al., 1971; Vesselinovitch et al., 1972, 1980; Rao and
Vesselinovitch, 1973; Moore et al., 1981; Kemp et al., 1989).
This sex difference in susceptibility is due in part to the
promotive effect of androgens secreted by the teste after
puberty (Vesselinovitch et al., 1980; Moore et al., 1981;
Kemp et al., 1989; Weghorst and Klaunig, 1989). Further-
more, several studies (Vesselinovitch and Mihailovich, 1967;
Vesselinovitch et al., 1980; Goldfarb and Pugh, 1990;
Yamamoto et al., 1991; Tsutsui et al., 1992) have shown that
ovariectomy after administation of carcinogens shortens the
latent period in the development of hepatoceliular tumours
and increases their incidence, indicating that the ovaries sup-
press hepatocellular tumorgeness These findinp suggt
that an ovarian hormone, oestrogen or progesterone, sup-
presses hepatoceilular tumorigenesis in mice.
Administration of 3'-methyl-4-dimethylaminoazobenzene
(3'-Me-DAB) to neonatal female mice induces hepatocellular
tumorigenesis (Roe et al., 1971; Yamamoto et al., 1991), and
ovariectomy promotes developmnt of hepatocelular
tumours (Yamamoto et al., 1991, 1993a; Tsutsui et al., 1992).
We have shown that the ovarian hormone oestradiol-17P (E2)
suppresses hepatocellular tumorigenesis, but that the other
ovarian hormone, progesterone, does not (Yamamoto et al.,
1991, 1993b). Moreover, we suggested that the suppressive
action of E2 is due not to its direct action on the liver but to
its indirect action on tissues other than the liver (Yamamoto
et al., 1993b).
Since oestrogen increases secretion of prolactin by the
pituitary gland (Chen et al., 1970; Meites, 1974), and sine
mouse liver contains prolactin receptors (Harigaya et al.,
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1988; Davis and Linzer, 1989), it is conceivable that prolactin
is an extrahepatic mediator of oestrogen's suppression of
hepatoceilular tumorigenesis. Therefore, to investigate the
role of prolactin in hepatocellular tumorigenesis in mice, we
emined hepatoclluar tumorigenesis induced by 3'-methyl-
4-dimethylamninoazoben e in mice under various serum
levels ofprolatin. We produced high serm levels of prolac-
tin by daily injections of perphenazine, a dopamine
antagonist (Wicha et al., 1980; Shinha and Gilligan, 1982;
Singtripop et al., 1991), or trnsplantation ofpituitary glands
under the renal capsule (Chen et al., 1970; Lam et al., 1976),
and decreased the oestrogen-induced high serum levels of
prolactin by daily injections of bromocripti, a dopamine
agonist (Mori and Nagasawa, 1984; Wood et al., 1991).
Materiaks and nto
Mice
Female C57BL/6 x DS-FI mice (bred in our laboratory) were
housed at 25C under controlled lighting (12 h light/12 h
darkness) and allowed free access to water and food pellets.
Ovariectomy was performed under pentobarbital sodium
Administration ofcarcinogen
The carcinogen, 3'-Me-DAB (ICN Pharmaceuticals, Plain-
view, NY, USA) was suspended in an aqueous solution of
0.7% (w/v) gelatin at a concentration of 10mgml'; 0.05 ml
of the suspension was injeted intraperitoneally into mice 10,
12, 14, 16 and 18 days old.
Implantation ofoestradiol-17P
Cylindrical choksterol pellets containing 1% (w/v) E2 were
prepaed. Ten milligram pellets were implanted sub-Pmbcai-an md ivrbmaien
R Yaato etal
cutaneously (s.c.) in the interscapular space. Pellets were
replaced every 3 months.
Injection ofperphenazine or bromocriptine
Perphenazine (Sigma, St Louis, MO, USA) was dissolved in
saline at a concentration of 1 mg ml ;0.1 ml of the solution
was injected s.c. daily. Bromocriptine (2-bromo-a-ergo-
criptine methanesulphonate salt) was dissolved in 10% (v/v)
ethanol in saline at a concentration of 1 mg ml'; 0.1 ml of
the solution was injected s.c. daily. Bromocriptine was kindly
supplied by Sandoz Pharmaceuticals (Tokyo, Japan).
Transplantation ofpituitary glands
Four pituitary glands obtained from 5 to 6-month-old female
C57BL/6 x DS-F1 mice that had received no treatments were
transplanted under the kidney capsule of 6-month-old mice
that had been treated with 3'-Me-DAB neonatally and under-
gone ovariectomy at 1 month of age.
Treatment ofmice
The study consisted in two experiments (experiments I and
II). All mice (318 mice) used in the experiments were treated
neonatally with 3'-Me-DAB as described above, and under-
went ovariectomy at I month of age. In experiment I (Figure
1), the mice were divided into four groups (groups 1, 2, 3 and
4). Group 1 mice (n = 35) received daily injections of saline
(0.1 ml) from the age of 6 months. Group 2 mice (n = 50)
received daily injections of perphenazine (0.1 mg) dissolved in
0.1 ml of saline. Group 3 mice (n = 48) received transplants
of four pituitary glands under the kidney capsule at 6 months
of age. Group 4 mice (n = 53) received implants of E2 pellets
(10 mg) at 1 month of age. In experiment II (Figure 2), the
mice were divided into three groups (groups 1, 2 and 3).
Group 1 mice (n = 54) received daily injections of 0.1 ml of
vehicle (10% ethanol in saline) from the age of 6 months.
Both groups 2 and 3 received implants of E2 pellets (10 mg)
at 1 month of age. In addition, group 2 mice (n = 38)
received daily injections of bromocriptine (0.1 mg) dissolved
in 0.1 ml of vehicle, while group 3 mice (n = 40) received
injections of vehicle (0.1 ml) only from the age of 6 months.
At 12 months of age, blood was taken from the inferior vena
cava of all mice under pentobarbital sodium anaesthesia,
after which the mice were killed by cervical dislocation and
their livers were promptly removed.
In experiment I. we examined the effects on hepatocellular
tumorigenesis of high serum levels of prolactin, produced by
either daily injections of perphenazine (Wicha et al., 1980;
Shinha and Gilligan, 1982; Singtripop et al., 1991) or trans-
plantation of pituitary glands (Chen et al.. 1970; Lam et al.,
1976) (Figure 1).
In experiment II. we investigated the effects of bromocrip-
tine, which decreases serum levels of prolactin (Mori and
Nagasawa, 1984; Wood et al., 1991), on the suppressive
action of oestrogen on hepatocellular tumorigenesis (Figure
2). Since our previous studies suggested that oestrogen exerts
its suppressive effect after 6 months of age (Tsutsui et al.,
1992; Yamamoto et al., 1993a), injections of perphenazine or
bromocriptine were started and pituitary glands were trans-
planted at that time.
Histological eramination ofthe liver
The liver was fixed in Zamboni's solution and cut into 4-mm-
thick serial strips. One section (5ILm) of each strip was
stained with haematoxylin and eosin; all such sections were
examined for nodular lesions, i.e. adenomatous nodules and
carcinomas. An adenomatous nodule of hepatocellular origin
was defined with reference to previous reports (Vesselinovitch
et al., 1978; Frith et al., 1980; Lipsky et al., 1981) as des-
cribed previously (Yamamoto et al., 1991) as a mixture of
eosinophilic, basophilic, vacuolated and foamy hepatocytes in
various proportions that compresses the adjacent paren-
Experime
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Fge 1 Design ofexperiment I. All female mice were treated
with 3'-Me-DAB neonatally and underwent ovanrectomy at I
month of age. Groups I and 2 received daily injections of saline
(0.1 ml) and perphenazine (0.1 mg in 0.1 ml of saline) from the
age of 6 months. Group 3 received transplants of four pituitary
glands under the kidney capsule at 6 months of age. Group 4
received implants of E2 pellets (10mg) at 1 month of age.
Experiment II
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Figure 2 Design of experiment II. All female mice were treated
with 3'-Me-DAB neonatally and underwent ovariectomy at 1
month of age. Group 1 received daily injections with 0.1 ml of
vehicle (10% ethanol in saline) from the age of 6 months. Groups
2 and 3 received implants of E2 pellets at 1 month of age. Group
2 received daily injections of bromocriptine (0.1 mg in 0.1 ml of
vehicle), and group 3 received vehicle (0.1 ml) only from 6
months of age.
chyma but does not contain a carcinomatous lesion with a
trabecular structure. Hepatocellular carcinoma was defined as
a nodular lesion with a trabecular structure, as described
previously (Yamamoto et al., 1991).
Number ofadenomatous nodules per mouse
All sections of the liver prepared as described above were
examined, and the number of adenomatous nodules was
counted. An adenomatous nodule found in two adjacent
sections was counted as one lesion.
Assay ofserwn prolactin
Serum was obtained by centrifugation of blood at 1000 g for
10 mmn, and was stored at - 80°C until assay. Serum prolac-
tin was determined by double-antibody radioimmunoassay
with materials and protocols supplied by AF Parlow
(Pituitary Hormones and Antisera Center, Harbor-UCLA
Medical Center, Torrance, CA, USA). Results are expressed
in terms of standard AFP6476C. All samples were assayed in
duplicate. The intra-assay and inter-assay variations were less




Statistical analysis was performed with the x2 test or
Student's t-test A P-value below 0.05 was considered
significant.
Ressts
Table I shows the effects of perphenaine or transplantaton
of pituitary glands on development of adenomatous nodules
induced by neonatally administered 3'-Me-DAB. The in-
cidence of adenomatous nodules in mice that had underne
ovariectomy at 1 month of age was 71.4% at 12 months of
age. Treatment with perphenaine from 6 months of age and
tanWlantation of pituitary glands at 6 months of age
significantly decreased the incidence of adenomatous nodules
to 16.0% and 20.6% ely, while implantation of E2
pellets at I month of age decreased the incidence to 1.9%.
However, the mean number of adenomatous nodules per
mouse was not significntly affected by treatment with per-
phenazine or transplantation of pituitary glands Treatment
with perphenazine and tansplantation of pituitary glands
markedly elevated serum levels of prolactin, and implanta-
tion of E2 pellets raised prolactin levels to an even greater
extent.
Table I shows the effects of bromocriptine on develop-
ment of adenomatous nodules in mice that had received
implants of E2 pellets. Implantation of E2 pellets at 1 month
of age markedly decreased the incidence of adenomatous
nodules at 12 months of age to 5.0%, while the incidence was
66.7% in mice that did not receive E2 pellets. Wben mice that
had received E2 pellets were treated with bromocriptine from
6 months of age, the incidence of adenomatous nodules
increasd to 23.7%. This incidence was lower
than that in mice that did not receive E2 pellets, and was




planted pituitary glands, as shown in Table I. The number of
adenomatous nodules was not signintly affected by either
implantation of E2 pellts or treatment with bromocriptine.
Serun prolatin kvels in mice that received E2 pellets were
extrmely high, in agreement with data shown in Table I.
Treatment with bromocriptine signifintly decreased serum
prolactin to levels similar to those in mice treated with
perphenazine or pituitary gland transplants, as shown in
Table I. No carcnomas were found in any groups. No
adenomatous nodules or carcinomas developed in the livers
of 21 female mice at 12 months of age which had not been
treated neonatally with 3'-Me-DAB, but had instead under-
gone ovariectomy at I month of age.
Incrases in serum levels of prolatin produced by injections
of prhai (dopamine antagonist) and by pituitary
grafts were accompanied by decreases in the incidence of
adenomatous nodules. The greater the increase in serum
klees ofprolactin produced by mplantation ofE2 pellets, the
greater was the decrease in the incidence ofnodules. Further-
more, bromocipne (dopamine agonist) decreased the high
serum levels of prolactin induced by implantation of E2
pellets and increased the incidence of adenomatous nodules.
Dopamine agonists and antagonists produce changes in
serum levels of prolactin (Shinha and Gilligan, 1982; Mon
and Nagasawa, 1984; Singtripop et al., 1991; Wood et al.,
1991), but have also been reported to exert other effects. For
example, it is reported that dopamine antagonists stimulate
aldosterone and corticosterone secretion in rats (Goebel et
al., 1992) and that bromocriptn increases serum levels of
growth hormone in normal human subjects (Wood et al.,
1991). Pituitary grafts secrete growth hormone as well as
prolactin (Blanck et al., 1984). Moreover, a recent report by
TableI Effectsofp zineortamnsplantationofpituitaryglandsonsermprolacuin kvels
and deveopment ofaenomatous nodules in the liver
Adwmmatous nodule Serun prolacti
Treament Incidmnr Nwnberper mowe (ngml')
Saline 25/35 (71.4%)r 2.5± 0.4 16.6 ±3J3 (n = -I)
Perpa 8/50 (16.0%)"" 1.5 ± 0.3 178.6 ± 17.2" (n = 20)
Transplantation of 10/48 (20.6%)" 1.4 ± 0.2 203.0± 22.2" (n = 17)
pituitary glands
Implantation of 1/53 (1.9%)d 1.0 1320.5 ± 158.9' (n = 15)
E2pelets
The experimental design is shown in Figure 1. Senum concentrations of prolactin were
measured mice,thenumberofwhichisshown mparentheses I xi catesthenumberof
mice with nodules out ofnumber ofmice examined, andpecentageinciden is
showninparenttss Numberpermouseindates thenumberofadenomatousnodules meach
mousewith atousnoduls 'Mean ± se."xP<0.05,signifiantdifference from thevalw
of mice pnted with E2 pelklts (by x2 test; -by Student's t-test). "P<0.05, nt
from the vale ofmice mijcted wnth saline alone('by X2 test; 'by Student's t-test).
TAe n Effects of brminjections on sermn prolcin ievels and develpment of
adenomatos noduls
Admomatous nodules Senu, prolactn
Treatmt hnidence Nwnberper mouse (g ng t)'
Vehicle 36/54 (66.7%) 1.9 ±0.3 14.9 ± 3.1c (n= 20)
Bro e 9/38 (23.7%)A 1.3 ± 0.2 164.5± 21.0 (n = 15)
and ntaon
ofE2pits
Implantation of 2/40 (5.0/) 1,2 818.5± 158.1' (n = 15)
E2pelts
The exprimental design is shown in Figure 2. Serum concwentions of prolactin were
measuedinmice,thenumberofwhichisshowninparentheses Inridencei ndtesthenumberof
mie ith adenomatous nodules out ofnumber ofmice examined, and p tage i is
showninparenth Nmberpermouseindicates thenumberofa usnodulesin h
mousewith ln tousnodules WMean ± se. 'wP<0.05,significantdifferenc from thevalue
of mimpc ated with E2 pellts (bby 2 test; -by Stu nt's t-test). UP<0.05, signficant
differce from the value ofmice injected with vehie alone (*by x2 test; -by Studet's f-test).Pralacin&uW kwbwmapgssis
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Ishibashi et al. (1994) that bromocriptine inhibits growth of
human small-cell lung cancer through tumour dopamine
receptors raises the possibility that dopamine agonists
and antagonists influence 3'-Me-DAB-induced tumorigenesis
through a direct effect on hepatocytes. Therefore, we cannot
exclude the possibility that the influences of perphenazine,
pituitary grafts and bromocriptine on liver tumorigenesis are
irrelevant to influences on serum levels of prolactin. How-
ever, our finding that the increase in serum levels of prolactin
was accompanied by a suppression of liver tumorigenesis in
mice supports the possibility that high serum levels ofprolac-
tin suppress development of 3'-Me-DAB-induced hepatocel-
lular tumours in mice. If this is true, then it is likely that the
suppressive action of oestrogen on hepatocellular tumori-
genesis in mice is mediated, at least in part, by prolactin
secreted by the pituitary glands.
In rats prolactin has been shown to induce hepatic
ornithine decarboxylase and plasminogen activator activity
and specific enzyme markers expressed early in the GI phase
of the cell cycle (Crowe et al., 1991), to cause hypomethyla-
tion of DNA in the liver (Reddy and Reddy,-1990), to
stimulate DNA synthesis by hepatocytes (Buckley et al.,
1986) and to produce hepatomegaly (Buckley et al., 1985).
Furthermore, it is reported that prolactin promotes develop-
ment of diethylnitrosamine-induced preneoplastic y-glutamyl-
transpeptidase-positive foci in the liver of female rats
(Buckley et al., 1985). Blank et al. (1987) reported that
prolactin did not suppress growth in male rats of y-glutamyl-
transferase-positive hepatic foci induced by diethylnitro-
samine followed by treatment with 2-acetylaminofluorene.
Thus, the effects of prolactin on the development of
carcinogen-induced hepatocellular tumours in rats may be
opposite to those in mice, although it is unknown whether
the effects of prolactin on normal hepatocytes differ in mice
and rats.
The effects of oestrogens on hepatocellular tumorigenesis
in rats are opposite to those in mice. In mice, a natural
oestrogen, E2, and a synthetic oestrogen, ethinyloestradiol,
have been reported to suppress carcinogen-induced hepato-
cellular tumorigenesis (Lee et al., 1989; Yamamoto et al.,
1993a,b). In contrast, in rats several synthetic oestrogens
have been shown to promote carcinogen-induced hepatocel-
lular tumorigenesis (Metzler and Degen, 1987; Campen et al.,
1990; Mayol et al., 1992). A synthetic oestrogen has been
shown to increase serum levels of prolactin (Campen et al.,
1990). Synthetic oestrogens may exert toxic effects on the
liver that contribute to the promotion of hepatocellular
tumorigenesis (Metzler and Degen, 1987). However, if the
promotive effects of synthetic oestrogens on hepatocellular
tumorigenesis are due to the high serum levels of prolactin
which they produce, the difference in the effects of oestrogens
on hepatocellular tumorigenesis in mice and rats might be
due to the difference in the effects of prolactin on hepatocel-
lular tumorigenesis.
In carcinogen-induced hepatocellular tumorigenesis in rats,
the difference in the secretory pattern of growth hormone is
due, at least in part, to the lesser susceptibility of females to
carcinogens; higher basal levels of serum growth hormone in
females suppresses hepatocellular tumorigenesis (Blank et al.,
1987; Hallstrom et al., 1991). The role of growth hormone in
suppression of hepatocellular tumorigenesis in female mice is
unknown, but the present results suggest that the pituitary
gland plays a role in hepatocellular tumorigenesis in mice.
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